12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Secukinumab: Phase II data

A double-blind, international Phase II trial in 73 patients with RRMS showed that IV secukinumab reduced the cumulative number of CUAL on brain MRI scans performed every 4th week from week 4 to 24, the primary endpoint, by 49% compared to placebo (p=0.087). Additionally, secukinumab led to a 67% reduction in cumulative new gadolinium-enhancing lesions on T1-weighted images compared to placebo (p=0.003). Furthermore, an...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >